BridgeBio Pharma, Inc.

BBIOSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1743881

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$9.3M	$77.6M	$69.7M	$8.2M	$40.6M
Cost of Goods and Services Sold	—	—	—	—	$2.7M
Research and Development Expense	$455.7M	$399.5M	$451.0M	$337.0M	$209.9M
Selling, General and Administrative Expense	$150.6M	$143.2M	$192.2M	$145.7M	$94.4M
Operating Expenses	—	—	—	—	—
Operating Income (Loss)	-$607.4M	-$512.2M	-$576.6M	-$474.5M	-$266.2M
Interest Expense	—	—	$46.8M	$36.7M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$919.3M	$546.4M	$623.0M	$1.0B	$703.6M
Assets, Current	$720.7M	$477.6M	$548.9M	$888.9M	$642.8M
Cash and Cash Equivalents, at Carrying Value	$375.9M	$376.7M	$393.8M	$356.1M	$363.8M
Accounts Receivable, after Allowance for Credit Loss, Current	$4.7M	$1.8M	—	—	—
Inventory, Net	$0.00	—	—	—	—
Liabilities	$2.4B	$1.9B	$1.9B	$1.9B	$595.7M
Liabilities, Current	$154.4M	$143.8M	$121.4M	$135.1M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$527.7M	-$419.5M	-$497.9M	-$399.7M	-$253.6M
Net Cash Provided by (Used in) Investing Activities	$54.0M	$453.1M	-$200.8M	-$53.0M	-$217.3M
Net Cash Provided by (Used in) Financing Activities	$451.5M	-$13.1M	$736.4M	$447.2M	$398.8M
Payments to Acquire Property, Plant, and Equipment	$1.3M	$4.8M	$13.2M	$7.5M	$2.6M
Payments of Dividends	—	—	—	—	—
Payments for Repurchase of Common Stock	$0.00	—	$200.0M	$75.0M	$75.0M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)